A study published in BMC Veterinary Research demonstrates the effectiveness of OKV-119, a miniature drug implant containing exenatide, in reducing weight in obese cats.
This implant leverages Vivani Medical’s patented NanoPortal technology, allowing long-term medication delivery through a subdermal implant. The exenatide drug is known for regulating blood sugar levels and promoting weight loss.
The study found that cats implanted with OKV-119 experienced significant weight reduction compared to controls. The implant’s sustained release of exenatide over 84 days effectively suppressed appetite and increased energy expenditure.
Feline obesity is a significant health concern, affecting up to 40% of domestic cats. This condition is associated with numerous health problems, including diabetes, heart disease, and joint pain.
The development of OKV-119 offers a promising therapeutic option for feline obesity. The implant’s convenient administration and extended duration of action make it a potential breakthrough in reducing animal obesity and improving overall feline health.
Researchers anticipate extending the implant’s duration to six months in future studies. This extended duration would further enhance the implant’s practicality and effectiveness in treating feline obesity in the long term.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
